Clemens Fischer Pushes German Brain-Computer Interface Program to Rival Elon Musk
Clemens Fischer’s Futrue Neurosciences secures approval for a cannabis-based pain drug and readies a brain-computer interface implant in Munich, challenging Neuralink.
Clemens Fischer, a 50-year-old physician-turned-entrepreneur based near Munich, has moved into the spotlight with a two-pronged advance: regulatory clearance for a cannabis-derived pain medication and a planned brain-computer interface implant trial at a Munich hospital. The developments mark a major step for Fischer’s Futrue Neurosciences as it positions itself alongside established firms pursuing neural implants. The combination of a newly approved drug and an imminent device trial signals an accelerated push into both pharmaceutical and neurotechnology markets.
Futrue Secures Regulatory Approval for Cannabis Pain Drug
Fischer’s company recently won authorization from Germany’s medicines regulator for Exilby, a novel cannabis-based medication aimed at chronic pain patients. The authorization makes Exilby one of the first standardized plant-derived medicines of its kind to gain formal recognition in the country. Company executives say the approval reflects years of development and substantial internal investment, positioning the product as an alternative to raw cannabis flower used under prescription.
The approval arrives amid growing demand for medical cannabis in Germany. In 2025 the country reimbursed more than 160,000 prescriptions for cannabis flowers and imported roughly 200 tonnes of the botanicals for therapeutic use, underscoring the scale of the market and the appeal of a standardized pharmaceutical option. Futrue argues that a regulated formulation will ease prescribing and reimbursement challenges faced by doctors, pharmacies and insurers.
Production Capacity and International Ambitions
Fischer controls cultivation operations in Denmark that he says can yield up to ten tonnes of raw cannabis annually, a volume the company claims would suffice for millions of medicine units. Futrue executives describe the supply chain as vertically integrated, from cultivation through processing to finished doses, enabling tighter quality control than ad hoc imports. That capability is central to the company’s plan to market Exilby beyond Germany, including intentions to enter European and U.S. markets.
The company reports that the development program cost several hundred million euros and was largely funded without external investors, according to Fischer. That financing model has allowed Futrue to pursue parallel initiatives across different therapeutic areas while retaining strategic control over product rollout and research priorities.
From Retail Brands to High-Tech Neuroscience
Fischer is better known to many consumers for over-the-counter health products and aggressive marketing of familiar remedies, but his corporate portfolio extends far beyond retail. The holding company in Gräfelfing houses roughly twenty businesses addressing varied therapeutic fields, with Futrue Neurosciences dedicated to neural interfaces. Executives characterize the group as a hybrid of consumer health and cutting-edge medical research.
That breadth reflects Fischer’s self-made trajectory: a medical doctorate and serial entrepreneurship that transitioned from retail and supplements toward regulated pharmaceuticals and now into neurotechnology. The pivot underscores a strategic belief that commercial scale and brand experience can be leveraged to support capital-intensive clinical development.
First Human Implant Trial Scheduled in Munich
Futrue Neurosciences plans to implant its first chip in a patient at the Klinikum Rechts der Isar in Munich within weeks, marking the company’s entry into clinical testing for brain-computer interfaces. Company statements indicate the initial trial will focus on therapeutic applications tied to pain modulation, rather than consumer features or cognitive augmentation. The procedure will be closely monitored under clinical protocols required for human research.
The trial represents an important milestone: translating laboratory work into a regulated clinical setting. If successful, the implant study could validate device safety and basic functionality, enabling larger trials and potential applications for paralysis or sensory restoration that Fischer has cited as long-term goals.
Competitive Positioning Against Neuralink and Others
Fischer has explicitly framed his effort as a challenge to established players in the neural implant field, including high-profile U.S. ventures. He asserts that Futrue possesses competitive electrodes, chips and software developed in Germany and aims to close any lead held by rivals “faster than they expect.” Company messaging emphasizes national manufacturing and an integrated technology stack as differentiators.
Industry analysts note, however, that several competitors have advanced further in device iteration and clinical experience. Building credibility in neurotechnology typically requires repeated clinical evidence, regulatory approvals and long-term safety data. Fischer’s public confidence and recent pharmaceutical success may attract attention, but converting that momentum into parity with global leaders will require years of rigorous trials.
Regulatory, Ethical and Technical Challenges Ahead
Experts warn that brain-computer interfaces face a complex matrix of hurdles beyond engineering, including ethical oversight, data security, and long-term biocompatibility. Implantable devices introduce unique risks and demand extensive safety monitoring, while therapeutic claims such as “switching off pain” necessitate robust clinical proof. Regulators in Europe and elsewhere have grown more exacting about device testing and post-market surveillance.
There are also societal and clinical questions about access, consent and the potential for non-therapeutic uses of neural interfaces. Futrue will be expected to demonstrate transparent trial protocols, stringent privacy safeguards for neural data, and a clear risk-benefit calculus for patients participating in early studies.
Clemens Fischer’s dual advances—an approved, standardized cannabis medication and an imminent brain-computer interface implant trial—place his enterprise at the intersection of pharmaceutical and neurotechnology ambitions. How quickly Futrue can translate laboratory designs into widely accepted medical devices will depend on trial outcomes, regulatory scrutiny and its ability to navigate technical and ethical complexities. The coming months will be tightly observed by clinicians, industry peers and regulators as the company seeks to move from promise to proven therapies.
